PI-RADS 3-5 lesions MRI pattern after prostate artery embolization
British Journal of Radiology · 01.06.2026 · 99 (1182) · 1178-1189
DOI: 10.1093/bjr/tqag062 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Radiology, online erschienen am 15.03.2026. Verfasst von Romain Bossi Croci und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Vascular and Oncological Interventional Radiology, University of Paris Cité, PARCC-INSERM Unité-970, Assistance Publique-Hôpitaux de Pa…. Hauptthemen laut MEDLINE: Embolization, Therapeutic, Magnetic Resonance Imaging, Prostate, Prostatic Neoplasms. Die Arbeit nennt 38 Literaturangaben.
Abstract (Originalsprache)
Objectives
To evaluate changes in Prostate Imaging Reporting and Data System (PI-RADS) ≥3 lesions on prostate MRI after prostate artery embolization (PAE) performed for lower urinary tract symptoms.
Methods
This retrospective single-center study included 18 consecutive patients, each presenting with 1 PI-RADS ≥3 prostatic images on pre-PAE MRI and who underwent follow-up MRI after PAE. We assessed changes in PI-RADS score, infarcted areas, and prostate volume.
Results
Before PAE, all 18 lesions (mean PSA density: 0.078) were either biopsy-negative (n = 4) or deemed not requiring biopsy based on multidisciplinary consensus (n = 12), except for 1 case of non-clinically significant prostate cancer identified before PAE and 1 patient with a PIRADS 4 lesion who declined biopsy. The mean delay to post-PAE MRI was 120 days. After PAE, no new PI-RADS ≥3 lesions appeared, and no lesion was upgraded. Both initially classified as PI-RADS 5 lesions (negative on biopsies) were downgraded to PI-RADS 1. Among the 6 PI-RADS 4 lesions, 3 remained stable, 2 were downgraded to PI-RADS 3, and 1 to PI-RADS 2. Of the 10 PI-RADS 3 lesions, 8 achieved PI-RADS 1 status, and 2 remained stable.
Conclusions
Following PAE, pre-existing PI-RADS ≥3 lesions demonstrate stability or reduction in PI-RADS on MRI. However, radiopathological correlation studies are warranted to estimate the diagnostic reliability of the PI-RADS score in the post-PAE settings. Advances in knowledge This study shows that PI-RADS ≥3 images are downgraded after PAE. It does not imply that potential prostate cancer can be cured by PAE.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Vascular and Oncological Interventional Radiology, University of Paris Cité, PARCC-INSERM Unité-970, Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Paris F-75015, France.
- Department of Urology, University of Paris Cité, INSERM Unité 1151 INEM/Necker, Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Paris F-75015, France.
- Department of Adult Radiology, University of Paris Cité, Assistance Publique-Hôpitaux de Paris, Hôpital Necker-Enfants malades, Paris F-75015, France.
- Laboratoire d'Imagerie Biomédicale (LIB), Sorbonne University, CNRS UMR 7371, INSERM U 1146, Paris F-75006, France.
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, United States.
ORCID-Profile: Romain Bossi Croci, Sylvain Bodard
Zitieren
APA
Bossi Croci, R., Sapoval, M., Dariane, C., Pellerin, O., Thiounn, N., Dean, C., Boeken, T., & Bodard, S. (2026). PI-RADS 3-5 lesions MRI pattern after prostate artery embolization. British Journal of Radiology, 99(1182), 1178-1189. https://doi.org/10.1093/bjr/tqag062
Vancouver
Bossi Croci R, Sapoval M, Dariane C, Pellerin O, Thiounn N, Dean C, et al. PI-RADS 3-5 lesions MRI pattern after prostate artery embolization. British Journal of Radiology. 2026;99(1182):1178-1189. doi:10.1093/bjr/tqag062
BibTeX
@article{BossiCroci2026,
author = {Bossi Croci, Romain and Sapoval, Marc and Dariane, Charles and Pellerin, Olivier and Thiounn, Nicolas and Dean, Carole and Boeken, Tom and Bodard, Sylvain},
title = {PI-RADS 3-5 lesions MRI pattern after prostate artery embolization},
journal = {British Journal of Radiology},
year = {2026},
volume = {99},
number = {1182},
pages = {1178--1189},
doi = {10.1093/bjr/tqag062}
}
EUVIMED